China Biologic Products Holdings Profit Margin

China Biologic Products Holdings's profit margin stands at 29.04% as of December 2020. That compares with 27.22% in the prior-year period — up 6.7% year over year. That is above the Healthcare sector average of 15.29%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

China Biologic Products Holdings reported 29.04% in profit margin versus 27.22% a year earlier — a 6.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

China Biologic Products Holdings sits higher the Healthcare benchmark (15.29%) with a profit margin of 29.04%. That is roughly 89.9% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 29.04% for China Biologic Products Holdings means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how China Biologic Products Holdings's profit margin evolved across reporting periods, while the comparison chart places CBPO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.